XSpray: Kallelse till årsstämma i Xspray Pharma AB publ

Håkan Danmyr

News; Instruments 15 sep. 2020 — Xspray Pharma AB (publ) engages in developing protein kinase inhibitors for targeted cancer treatments in Sweden. The kr2.3b market-cap Xspray Pharma Ab (publ) Share Chat - 0GHZ. Current Price. 78.80. 0.00.

XSPRAY PHARMA AB (PUBL) 0GHZ Overview - Search stock, chart, recent trades, company information, trading information, company news, fundamentals. Xspray Pharma. ISIN SE0009973563; Post-Trading. REAL-TIME. 17:29:46 CET. Last traded on 2021-04-13 17:29:46.

Prenumerera här. Redeye: Xspray Pharma - On the right track fre, sep 14, 2018 07:48 CET. Xspray has announced positive bioequivalence data with HyNap-Dasa, a step in the right direction which puts the company on track to execute on their business plan. We see the news as positive and indicative of news to come.

Håkan Danmyr

Company profile page for XSpray Pharma AB including stock price, company news, press releases, executives, board members, and contact information XSPRAY PHARMA AB (PUBL) : Financial news and information Stock XSPRAY PHARMA AB (PUBL) | NASDAQ STOCKHOLM AB: XSPRAY | NASDAQ STOCKHOLM AB View the latest share news for XSPRAY PHARMA AB (PUBL) and STO:XSPRAY RNS announcements, along with all the share chat by members of the Stockopedia community XSPRAY PHARMA AB (PUBL) : Press releases relating to XSPRAY PHARMA AB Most Read News. Hot News. Top Fundamentals. Top Capitalization.

Xspray Pharma genomför en nyemission inför - Redeye.se

XSPRAY PHARMA AB (PUBL) : News, information and stories for XSPRAY PHARMA AB (PUBL) | Nasdaq Stockholm: XSPRAY | Nasdaq Stockholm Xspray Pharma publishes its annual report for 2020 Press release 2021-03-18 Xspray Pharma aims to submit its improved version of dasatinib for market approval application in second half of 2021 Press release 2021-03-05 Xspray Pharma publishes its annual report for 2020 Press release 2021-03-18 Xspray Pharma aims to submit its improved version of dasatinib for market approval application in second half of 2021 Press release 2021-03-05 View the latest XSpray Pharma AB (XSPRAY) stock price, news, historical charts, analyst ratings and financial information from WSJ. XSPRAY PHARMA AB (PUBL) : Financial news and information Stock XSPRAY PHARMA AB (PUBL) | NASDAQ STOCKHOLM AB: XSPRAY | NASDAQ STOCKHOLM AB Find the latest Xspray Pharma AB (XSPRAY.ST) stock quote, history, news and other vital information to help you with your stock trading and investing. About Xspray Pharma Xspray Pharma AB (publ) is a product development company with multiple product candidates in clinical development. Xspray uses its innovative, patented RightSize technology to develop improved and generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) announces today that its improved version of Sprycel® (dasatinib), HyNap-Dasa 505(b)(2), is expected to show a significantly improved product profile and a more effective absorption, which in turn leads to medically relevant improvements for patients. This version is based on the thoroughly tested “A” formulation and will be […] Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo, HyNap-Sora, and HyNap-Dasa.

Köp aktien Xspray Pharma AB (XSPRAY).
Syntheticmr avanza

Redeye: Xspray Pharma - On the right track fre, sep 14, 2018 07:48 CET. Xspray has announced positive bioequivalence data with HyNap-Dasa, a step in the right direction which puts the company on track to execute on their business plan. We see the news as positive and indicative of news to come. Xspray Pharma / ANDA vs 505 (b) (2) / ANDA vs 505 (b) (2) 2021-04-09 12:42 Generika måste vara helt identisk med originalprodukten ifråga om dos, administration, upptag etc. Kan man visa detta registrerar man via ANDA och produkten kallas då generika. Xspray Pharma AB (publ) är ett produktutvecklingsföretag med flera produktkandidater i klinisk utveckling.

Home · Results · Broker Views · Director Dealings · IPO Centre · Company Diary · Regulatory News · Company A-Z. Market Data.
Bodelning arvskifte särkullbarn

recipharm ir
habiliteringen motala mjölby
camping landskrona kommun
sage the gemini now and later
bastu med havsutsikt

Xspray Pharma AB XSPRAY aktie - Nordnet

Sobi Avanza Forum : Frivilligt. Director Regulatory Affairs på Ascelia Pharma AB. för 6 dagar sedan — Alla förlorare QuiaPEG Pharmaceuticals Holding AB, -11,26%.

Avista kurser nordea
yrkesgymnasiet huddinge antagningspoäng

Xspray Pharma genomför en nyemission inför - Redeye.se

Note that the company may have other share series admitted to trading and that it may have unlisted shares. Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo, HyNap-Sora, and HyNap-Dasa. The co Køb Xspray Pharma AB (XSPRAY) aktien. Hos Nordnet kan du handle fra 0 kr.